Aprea Therapeutics
NASDAQ: APREDoylestown, US · Delaware corporation · 1 known investors
Founders & leadership
JP
John P. HamillExecutive
OG
Oren GiladExecutive
Board
JB
Jean-Pierre BizzariBoard director
GG
Gabriela GruiaBoard director
RP
Rifat PamukcuBoard director
BS
Bernd SeizingerBoard director
MD
Marc DueyBoard director
JB
John B. HennemanBoard director
MG
Michael GrissingerBoard director
RP
Richard PetersBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$3.1M disclosed across 1 round · 2025
▶$3.1MraisedDec 2025 · 8 investors · BiotechnologyRule 506(b)
▶$3.1MraisedDec 2025 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John P. HamillExecutive Officer
- Jean-Pierre BizzariDirector
- Gabriela GruiaDirector
- Rifat PamukcuDirector
- Bernd SeizingerDirector
- Marc DueyDirector
- John B. HennemanDirector
- Oren GiladExecutive Officer, Director
- Michael GrissingerDirector
- Richard PetersDirector
- Offering amount
- $5.8M
- Amount sold
- $3.1M
- Sales commissions
- $210K
- Placement agents
- Maxim Group LLC
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Aprea Therapeutics's investors?
- Aprea Therapeutics's investors include HealthCap.
- How much funding has Aprea Therapeutics raised?
- Aprea Therapeutics has disclosed $3.1M raised across 1 round.
- Where is Aprea Therapeutics headquartered?
- Aprea Therapeutics is headquartered in Doylestown, US.